The record breaking $74 billion BMS-Celgene takeover just got the green light from 2 key players

Institutional Shareholder Services and Glass Lewis, two influential voices in corporate brawls, have come out in favor of Bristol-Myers Squibb's $74 billion takeover of the biotech Celgene.
The deal has faced growing unhappiness from shareholders, especially the vocal activist Starboard.
Investors are set to vote on the deal at an April 12 meeting, and the acquisition is likely to go through, the Jefferies analyst Michael Yee has said.Two key voices in corporate brawls have weighed in on the pha